Tiziana Life Sciences Interview to Air on Bloomberg Television US on the RedChip Money Report

Tiziana Life Sciences Interview to Air on Bloomberg Television US on the RedChip Money Report
Tiziana Life Sciences to Present at the BIO CEO & Investor Digital Conference
NEW YORK and LONDON – February 5, 2021 (GLOBE NEWSWIRE) – Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative
Tiziana Life Sciences CEO Discusses COVID-19 Trial Data in Exclusive Interview
Tiziana Reports Positive Data from the Clinical Study of Nasal Administration with Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, in COVID-19 Patients in Brazil
New York/London, 26 January 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and
AIM Delisting and Admission to the Standard Listing Segment of Main Market
Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer
NEW YORK and LONDON – 11 January 2021 (GLOBE NEWSWIRE) – Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative
Tiziana announces completion of the clinical trial with nasally administered Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, for the treatment of COVID-19 patients in Brazil
Phase 1b/2 Clinical Trial – Crohn’s Disease